

# CITATION REPORT

List of articles citing

Duration of action of sildenafil citrate in men with  
erectile dysfunction

DOI: 10.1111/j.1743-6109.2004.04026.x

Journal of Sexual Medicine, 2004, 1, 179-84.

**Source:** <https://exaly.com/paper-pdf/36831202/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 680-91	2.9	61
40	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 848-55	1.1	30
39	Introduction. <i>Urology</i> , <b>2006</b> , 68, 1-5	1.6	0
38	Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. <i>Urology</i> , <b>2006</b> , 68, 689-96	1.6	27
37	Erection hardness: a unifying factor for defining response in the treatment of erectile dysfunction. <i>Urology</i> , <b>2006</b> , 68, 17-25	1.6	53
36	Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). <i>Urology</i> , <b>2006</b> , 68, 26-37	1.6	41
35	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. <i>International Journal of Impotence Research</i> , <b>2006</b> , 18, 423-31	2.3	26
34	Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 662-667	1.1	112
33	Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 154-60	2.3	23
32	Correlations between increased erection hardness and improvements in emotional well-being and satisfaction outcomes in men treated with sildenafil citrate for erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 398-406	2.3	20
31	Are consecutive nightly recordings required for valid evaluation of sleep-associated erections?. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 196-9	2.3	4
30	Quality of erection questionnaire correlates: change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2007</b> , 4, 83-92	1.1	34
29	Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. <i>Journal of Sexual Medicine</i> , <b>2007</b> , 4, 137-144	1.1	9
28	The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 1636-45	1.1	23
27	Sexual attitude and perception on sexual relationship among long-term users of sildenafil. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 2681-7	1.1	10
26	Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. <i>Urology</i> , <b>2008</b> , 71, 686-92	1.6	17
25	Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model. <i>Journal of Clinical Pharmacology</i> , <b>2008</b> , 48, 1237-41	2.9	9

24	Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 388-95	2.3	4
23	Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 333-42	2.3	37
22	Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 2836-50	1.1	5
21	Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. <i>International Urology and Nephrology</i> , <b>2009</b> , 41, 287-92	2.3	19
20	Toward a new LEPOCHb optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1214-30	2.9	17
19	Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. <i>Urology</i> , <b>2009</b> , 74, 831-836.e8	1.6	34
18	Effect of sildenafil on penile plethysmography responding: a pilot investigation. <i>Archives of Sexual Behavior</i> , <b>2010</b> , 39, 1449-52	3.5	5
17	Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2209-2216	1.1	20
16	Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms. <i>Molecular Pharmacology</i> , <b>2010</b> , 77, 670-7	4.3	18
15	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 1427-37	5.9	61
14	Inhibidores de la fosfodiesterasa 5: calidad de la erección y repercusión emocional en los varones con disfunción eréctil y sus parejas. <i>Revista Internacional De Andrología</i> , <b>2010</b> , 8, 155-164	0.6	2
13	Future prospects in the treatment of erectile dysfunction: focus on avanafil. <i>Drug Design, Development and Therapy</i> , <b>2011</b> , 5, 435-43	4.4	14
12	Avanafil for treatment of erectile dysfunction: review of its potential. <i>Vascular Health and Risk Management</i> , <b>2012</b> , 8, 517-23	4.4	29
11	A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. <i>BJU International</i> , <b>2013</b> , 111, 137-47	5.6	23
10	Improvement in symptoms of peripheral arterial disease with sildenafil therapy. <i>Scottish Medical Journal</i> , <b>2013</b> , 58, e7-9	1.8	2
9	Exploring the association between erectile rigidity and treatment adherence with sildenafil. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1861-6	1.1	5
8	Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 701-11	2.9	13
7	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. <i>International Journal of Impotence Research</i> , <b>2014</b> , 26, 223-9	2.3	12

6	Vardenafil dihydrochloride. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , <b>2014</b> , 39, 515-44	3	7
5	Overview of the synthetic routes to sildenafil and its analogues. <i>Synthetic Communications</i> , <b>2017</b> , 47, 1269-1300	1.7	5
4	Modeling Human Sexual Motivation in Rodents: Some Caveats. <i>Frontiers in Behavioral Neuroscience</i> , <b>2019</b> , 13, 187	3.5	14
3	Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	5
2	An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. <i>Asian Journal of Andrology</i> , <b>2015</b> , 17, 61-7	2.8	12
1	Sex and Pharmacological Sexual Enhancement. <b>2017</b> , 387-411		